Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$48.42 USD

48.42
1,273,795

-0.25 (-0.51%)

Updated May 20, 2024 04:00 PM ET

After-Market: $48.45 +0.03 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (190 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down

by Zacks Equity Research

AstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects revenues and EPS to increase at a low double-digit to low teens percentage in 2024 at CER.

AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates

by Kinjel Shah

Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.

TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up

by Zacks Equity Research

TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.

Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down

by Zacks Equity Research

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Eli Lilly's (LLY) fourth-quarter conference call, investor focus is likely to be on the sales performance of its tirzepatide medicines, Mounjaro and Zepbound.

Regeneron (REGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports its fourth-quarter 2023 results.

Why Sanofi (SNY) Might Surprise This Earnings Season

by Zacks Equity Research

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Novo Nordisk (NVO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Novo Nordisk's (NVO) sales in fourth-quarter 2023 are expected to have been driven by increased Diabetes and Obesity Care product sales despite pricing pressure in the United States.

Can Amgen (AMGN) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Denali's (DNLI) Pipeline Progresses Despite Stiff Competition

by Zacks Equity Research

Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX

by Kinjel Shah

J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.

Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More

by Zacks Equity Research

Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Pfizer (PFE) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Pfizer's (PFE) revenues are expected to have declined in the fourth quarter of 2023 due to a steep decline in sales of its COVID-19 products on lower demand.

Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi

by Zacks Equity Research

Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Analyst Blog Highlights Adobe, IBM, Sanofi, Enbridge and Itau Unibanco

by Zacks Equity Research

Adobe, IBM, Sanofi, Enbridge and Itau Unibanco are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Adobe, IBM & Sanofi

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), International Business Machines Corporation (IBM) and Sanofi (SNY).

Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US

by Zacks Equity Research

The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.

IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why

by Zacks Equity Research

IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.

Sheraz Mian headshot

Top Research Reports for Meta Platforms, Broadcom & Verizon

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Broadcom Inc. (AVGO) and Verizon Communications Inc. (VZ).